Hong-Tao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hong-Tao Xu has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- En-Hua Wang
Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China
24 shared publications Yang Liu
Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang
17 shared publicationsEn-Hua Wang
Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang 110001, China
16 shared publicationsYuan Miao
Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China
14 shared publicationsLian-He Yang
Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China
12 shared publications- Lian-He Yang
Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China
11 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in Asian Journal of Surgery
Granular cell tumor of the trachea: A case report
- 25 September 2026
- Published by Elsevier in Asian Journal of Surgery
Open AccessGranular cell tumor of the trachea: A case report
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
LKB1 attenuates the transport activity of GLUT1 by regulating the alternative splicing of PKM1/PKM2 in cervical cancer
Wu M, et al. J Gynecol Oncol. 2026 ;37:e117. https://doi.org/10.3802/jgo.2026.37.e117
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Open AccessLKB1 attenuates the transport activity of GLUT1 by regulating the alternative splicing of PKM1/PKM2 in cervical cancer
Wu M, et al. J Gynecol Oncol. 2026 ;37:e117. https://doi.org/10.3802/jgo.2026.37.e117
- Open Access
- 28 November 2025
- Published by Elsevier in Asian Journal of Surgery
Squamous eccrine ductal carcinoma of the nose: A rare sweat gland tumor often misdiagnosed as squamous cell carcinoma
- 28 November 2025
- Published by Elsevier in Asian Journal of Surgery
Open AccessSquamous eccrine ductal carcinoma of the nose: A rare sweat gland tumor often misdiagnosed as squamous cell carcinoma
- Open Access
- 29 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 262
Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors
NRG1 fusion is an emerging oncogenic driver, and the FDA has approved drugs for the treatment of non-small cell lung cancer and pancreatic cancer associated with NRG1 fusions. This study retrospectively analyzed data from 25,203 patients with solid tumors who underwent next-generation sequencing (NGS) and identified 49 patients with NRG1 fusions. The mutation profiles and actionable therapeutic targets were analyzed among patients with fusions. In this study, 0.2% (49/25,203) of patients harbored NRG1 fusions. The frequencies of NRG1 fusions across various cancer types were as follows: prostate cancer, 0.65%; breast cancer, 0.47%; lung cancer, 0.29%; esophageal cancer, 0.25%; colorectal cancer, 0.17%; gastric cancer, 0.13%; pancreatic cancer, 0.11%; and hepatocellular carcinoma, 0.05%). A total of 36 fusion partners were detected, among which CD74 was predominant, accounting for 29.3% of cases. Patients with NRG1 fusions presented a greater frequency of FGFR1 mutations and RET fusions, compared with non-NRG1 fusion patients. Most lung cancer and colorectal cancer patients with NRG1 fusions harbored FDA-approved or potential drug targets, whereas those diagnosed with breast cancer harbored fewer such targets. NRG1 fusion-related drugs can provide additional treatment options. Our study expands the NRG1 fusion gene landscape and provides a valuable reference for the comprehensive treatment of patients with NRG1 fusions.
- 29 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 262
Open AccessComprehensive identification of NRG1 fusions in 25,203 patients with solid tumors
NRG1 fusion is an emerging oncogenic driver, and the FDA has approved drugs for the treatment of non-small cell lung cancer and pancreatic cancer associated with NRG1 fusions. This study retrospectively analyzed data from 25,203 patients with solid tumors who underwent next-generation sequencing (NGS) and identified 49 patients with NRG1 fusions. The mutation profiles and actionable therapeutic targets were analyzed among patients with fusions. In this study, 0.2% (49/25,203) of patients harbored NRG1 fusions. The frequencies of NRG1 fusions across various cancer types were as follows: prostate cancer, 0.65%; breast cancer, 0.47%; lung cancer, 0.29%; esophageal cancer, 0.25%; colorectal cancer, 0.17%; gastric cancer, 0.13%; pancreatic cancer, 0.11%; and hepatocellular carcinoma, 0.05%). A total of 36 fusion partners were detected, among which CD74 was predominant, accounting for 29.3% of cases. Patients with NRG1 fusions presented a greater frequency of FGFR1 mutations and RET fusions, compared with non-NRG1 fusion patients. Most lung cancer and colorectal cancer patients with NRG1 fusions harbored FDA-approved or potential drug targets, whereas those diagnosed with breast cancer harbored fewer such targets. NRG1 fusion-related drugs can provide additional treatment options. Our study expands the NRG1 fusion gene landscape and provides a valuable reference for the comprehensive treatment of patients with NRG1 fusions.
- Open Access
- 12 April 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (7) , 4462-4463
Tumor-to-tumor metastasis of papillary thyroid carcinoma to lung adenocarcinoma
- 12 April 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (7) , 4462-4463
Open AccessTumor-to-tumor metastasis of papillary thyroid carcinoma to lung adenocarcinoma
- Open Access
- 26 September 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (3) , 1819-1820
Primary thymic enteric-type adenocarcinoma: A rare thymic tumor
- 26 September 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (3) , 1819-1820
Open AccessPrimary thymic enteric-type adenocarcinoma: A rare thymic tumor
- Open Access
- 16 July 2024
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (3) , 1-7
Papillary adenoma of the lung: A case report and literature review
Papillary adenoma of the lung, a rare and benign tumor, is easily confused with other primary benign or malignant lung tumors and especially with lung adenocarcinoma that has a papillary growth pattern. Enhanced understanding and an accurate diagnosis of papillary adenomas of the lung are crucial for clinical treatment and prognostic assessment. A 61‑year‑old man who presented with an opportunistic finding in relation to a left lower lobe lung nodule during an examination was admitted to The First Hospital of China Medical University (Shenyang, China) for further treatment. Computed tomography (CT) revealed a well‑circumscribed left lower lobe nodule (diameter, ~1 cm), comprising branched papillae with a fibrovascular core and no other structural components. The tumor cells appeared relatively uniform in shape and well arranged with round or oval nuclei. No nucleoli or mitotic figures were observed. Immunohistochemically, the papillary structures of the tumor cells were strongly and diffusely positive for cytokeratin (CK), CK7, Napsin‑A and thyroid transcription factor 1. The Ki‑67 index was ~1%. A pathological diagnosis of primary papillary adenoma of the lung was made based on these findings. A left lower‑lobe wedge resection was performed and the patient's postoperative course was uneventful. Surgical resection is the preferred treatment. Papillary adenoma of the lung is very rare, and its clinical manifestations and CT images are non‑specific. It is important to avoid misdiagnosing of papillary adenoma of the lung as another type of lung tumor, especially adenocarcinoma. A clear understanding of the morphological and immunohistochemical features of papillary adenomas is important for the diagnosis of this rare lung tumor.
- 16 July 2024
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (3) , 1-7
Open AccessPapillary adenoma of the lung: A case report and literature review
Papillary adenoma of the lung, a rare and benign tumor, is easily confused with other primary benign or malignant lung tumors and especially with lung adenocarcinoma that has a papillary growth pattern. Enhanced understanding and an accurate diagnosis of papillary adenomas of the lung are crucial for clinical treatment and prognostic assessment. A 61‑year‑old man who presented with an opportunistic finding in relation to a left lower lobe lung nodule during an examination was admitted to The First Hospital of China Medical University (Shenyang, China) for further treatment. Computed tomography (CT) revealed a well‑circumscribed left lower lobe nodule (diameter, ~1 cm), comprising branched papillae with a fibrovascular core and no other structural components. The tumor cells appeared relatively uniform in shape and well arranged with round or oval nuclei. No nucleoli or mitotic figures were observed. Immunohistochemically, the papillary structures of the tumor cells were strongly and diffusely positive for cytokeratin (CK), CK7, Napsin‑A and thyroid transcription factor 1. The Ki‑67 index was ~1%. A pathological diagnosis of primary papillary adenoma of the lung was made based on these findings. A left lower‑lobe wedge resection was performed and the patient's postoperative course was uneventful. Surgical resection is the preferred treatment. Papillary adenoma of the lung is very rare, and its clinical manifestations and CT images are non‑specific. It is important to avoid misdiagnosing of papillary adenoma of the lung as another type of lung tumor, especially adenocarcinoma. A clear understanding of the morphological and immunohistochemical features of papillary adenomas is important for the diagnosis of this rare lung tumor.
- Open Access
- 7 May 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (9) , 3921-3922
Multifocal pseudomyogenic hemangioendothelioma of the thigh: A case report
- 7 May 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (9) , 3921-3922
Open AccessMultifocal pseudomyogenic hemangioendothelioma of the thigh: A case report
- Open Access
- 16 April 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 12 (11) , 1857-1862
Primary pulmonary meningioma and minute pulmonary meningothelial-like nodules: Rare pulmonary nodular lesions requiring more awareness in clinical practice
In this editorial, we comment on an article by Ruan et al published in a recent issue of the World Journal of Clinical Case. Pulmonary meningothelial proliferative lesions, including primary pulmonary meningiomas, minute pulmonary meningothelial-like nodules, and metastatic pulmonary meningiomas are rare pulmonary lesions. These lesions are difficult to differentiate from lung cancers based on clinical and imaging manifestations. Herein, we briefly introduce the clinical, imaging, and pathological characteristics of these lesions and discuss their pathogenesis to strengthen the current understanding of pulmonary meningothe lial proliferative lesions in clinical diagnosis and therapy.
- 16 April 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 12 (11) , 1857-1862
Open AccessPrimary pulmonary meningioma and minute pulmonary meningothelial-like nodules: Rare pulmonary nodular lesions requiring more awareness in clinical practice
In this editorial, we comment on an article by Ruan et al published in a recent issue of the World Journal of Clinical Case. Pulmonary meningothelial proliferative lesions, including primary pulmonary meningiomas, minute pulmonary meningothelial-like nodules, and metastatic pulmonary meningiomas are rare pulmonary lesions. These lesions are difficult to differentiate from lung cancers based on clinical and imaging manifestations. Herein, we briefly introduce the clinical, imaging, and pathological characteristics of these lesions and discuss their pathogenesis to strengthen the current understanding of pulmonary meningothe lial proliferative lesions in clinical diagnosis and therapy.